Is Atea Pharmaceuticals, Inc. (AVIR) Halal?

NASDAQ Healthcare United States $408M
✗ NOT HALAL
Confidence: 83/100
Atea Pharmaceuticals, Inc. (AVIR) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.4% is acceptable, the cash and interest-bearing securities ratio of 98.8% exceeds the 30% threshold. Atea Pharmaceuticals, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.4%
/ 30%
98.8%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 0.4%
/ 33%
98.8%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 0.4%
/ 33%
97.9%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.4%
/ 33%
98.8%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 0.4%
/ 33%
97.9%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.94
P/B Ratio
1.5
EV/EBITDA
-0.6
EV: $107M
Revenue
$0
Beta
0.3
Low volatility
Current Ratio
7.8

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -44.3%
Return on Assets (ROA) -28.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$132M
Free Cash Flow-$132M
Total Debt$843,000
Debt-to-Equity0.3
Current Ratio7.8
Total Assets$315M

Price & Trading

Last Close$5.33
50-Day MA$4.76
200-Day MA$3.67
Avg Volume551K
Beta0.3
52-Week Range
$2.46
$6.45

About Atea Pharmaceuticals, Inc. (AVIR)

CEO
Dr. Jean-Pierre Sommadossi Ph.D.
Employees
55
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$408M
Currency
USD

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. (AVIR) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Atea Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Atea Pharmaceuticals, Inc.'s debt ratio?

Atea Pharmaceuticals, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.

What are Atea Pharmaceuticals, Inc.'s key financial metrics?

Atea Pharmaceuticals, Inc. has a market capitalization of $408M. Return on equity stands at -44.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.